Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoid Syndrome: full-pipeline trial registry
1 of 5 indexed Carcinoid Syndrome trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Carcinoid Syndrome: 5 US clinical trials tracked, 1 recruiting.
Carcinoid Syndrome is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is TerSera Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition carcinoid-syndrome
OPEN 1 | RECR 20% | LATE 2 | EARLY 2 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Carcinoid Syndrome lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoid Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoid Syndrome is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Carcinoid Syndrome research.
TerSera Therapeutics accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoid Syndrome enrolment sits around 135 participants.
Median target enrolment is 135 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Carcinoid Syndrome research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals
NCT07087054
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
M.D. Anderson Cancer Center
NCT04993261
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
TerSera Therapeutics
NCT03223428
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Lexicon Pharmaceuticals
NCT01677910
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
Barbara Ann Karmanos Cancer Institute
NCT03453489
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoid Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoid Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoid Syndrome page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Carcinoid Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- TerSera Therapeutics sponsors the most Carcinoid Syndrome trials on record, review their full trial history before evaluating a specific study. See TerSera Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoid Syndrome condition card totals 5 registered trials; most-linked intervention Placebo-matching telotristat etiprate; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.